When the Department of Justice announced its historic federal medical cannabis rescheduling order on April 23, 2026, state cannabis regulators immediately faced a common challenge: determining how the new federal framework would affect their own licensing systems, regulatory programs, and compliance expectations.
Michigan’s Cannabis Regulatory Agency (CRA) responded the same day with a measured and cautious public statement.
Unlike agencies that immediately attempted to interpret every implication of the federal order, the CRA acknowledged both the significance of the announcement and the uncertainty surrounding its implementation. The agency stated that federal rescheduling represented a “historic and significant development,” but emphasized that “the details and practical implications of the change are still under review.“¹
The agency did more than simply acknowledge the federal action.
It publicly committed to conducting “a thorough analysis” of the Department of Justice’s final order to determine its scope, its impact upon Michigan operations, policies, and compliance obligations, and to provide “more detailed information, including any necessary adjustments or next steps.” Until that review was completed, the CRA advised licensees to continue operating under existing Michigan requirements and previously issued guidance.²
For Michigan licensees, attorneys, investors, and other stakeholders, the announcement struck a careful balance.
The CRA neither minimized the significance of the federal order nor rushed into premature legal conclusions. Instead, it promised additional guidance after completing its review.
Three months later, that promise raises an important question.
Where is that additional guidance?
This question should not be misunderstood as criticism.
Administrative agencies frequently require substantial time to evaluate significant federal regulatory changes. Cannabis regulation involves overlapping state statutes, administrative rules, federal controlled-substance law, taxation, banking, licensing, enforcement, and public health considerations. Responsible agencies often proceed deliberately rather than issuing immediate legal interpretations that may later require revision.
Nevertheless, public guidance serves an important regulatory function.
Cannabis businesses make operational decisions every day.
They evaluate expansion opportunities.
They negotiate financing.
They develop compliance programs.
They plan tax strategies.
They determine whether additional legal analysis or regulatory filings may become necessary.
Clear communication from regulators reduces uncertainty even when agencies ultimately conclude that existing rules remain unchanged.
Michigan itself has previously recognized the importance of that communication.
Months before the Department of Justice issued its final order, CRA Executive Director Brian Hanna warned that federal rescheduling alone would accomplish relatively little without coordinated implementation across multiple federal agencies. In comments submitted during the federal rescheduling proceedings, the CRA argued that businesses would require clear guidance addressing banking, taxation, enforcement, research, oversight, and implementation rather than merely a change in marijuana’s scheduling classification.³
The CRA reiterated that same philosophy following President Trump’s December 2025 Executive Order directing federal agencies to move toward Schedule III.
At that time, the agency stated that rescheduling would not automatically resolve the practical challenges facing state-regulated cannabis markets and emphasized that meaningful reform required coordinated implementation accompanied by clear governmental guidance.⁴
That earlier position provides important context for the CRA’s April 23 announcement.
Michigan entered the federal rescheduling process already recognizing that implementation—not merely legal classification—would determine the practical consequences for regulated businesses.
Consequently, when the CRA promised a comprehensive review followed by additional guidance, stakeholders reasonably anticipated a future document explaining how Michigan viewed the federal changes and whether state licensees should expect any operational adjustments.
A review of the CRA’s publicly available news releases published after April 23 reveals continued agency activity across numerous regulatory areas.
The CRA announced disciplinary actions against licensees, voluntary product recalls, formal administrative complaints, public hearings concerning marijuana administrative rules, leadership appointments, and ongoing rulemaking initiatives.⁵
Those announcements demonstrate that the agency has remained actively engaged in regulating Michigan’s cannabis industry.
However, the publicly available news releases reviewed for this article do not appear to include the type of comprehensive implementation guidance specifically contemplated by the CRA’s April 23 announcement concerning the federal medical cannabis rescheduling order.⁶
That observation should be understood carefully.
It does not establish that the CRA has performed no internal legal analysis.
Nor does it suggest the agency has abandoned its review.
Rather, it indicates that the comprehensive public implementation guidance promised in April does not appear among the agency’s publicly available announcements reviewed through late July 2026.
That distinction matters.
Internal legal analysis and public regulatory guidance serve different purposes.
One assists agency decision-making.
The other assists regulated businesses attempting to understand how those decisions affect day-to-day operations.
What Michigan Publicly Promised
The CRA’s April 23 announcement deserves careful examination because of both what it said and what it did not say.
The agency did not announce emergency administrative rules.
It did not immediately revise licensing requirements.
It did not instruct businesses to pursue DEA registration.
It did not conclude that Michigan licensees automatically qualified under the federal medical cannabis framework.
Nor did it announce that state regulations would remain permanently unchanged regardless of future federal implementation.
Instead, the CRA adopted a deliberately measured position.
The agency acknowledged that the Department of Justice’s order represented a significant federal policy change while emphasizing that its practical implications required additional legal and regulatory analysis.¹
That distinction is important.
Administrative agencies frequently confront major federal developments before the full legal consequences become apparent. In those circumstances, regulators often have two choices.
The first is to issue immediate guidance based upon preliminary legal analysis.
The second is to acknowledge the development, preserve regulatory stability by directing licensees to continue complying with existing requirements, and conduct a more comprehensive review before announcing whether changes will become necessary.
Michigan chose the second approach.
From a regulatory perspective, that decision was understandable.
Federal medical cannabis rescheduling immediately implicated numerous areas of law extending beyond traditional cannabis licensing.
Among the questions facing regulators were:
- Whether existing Michigan medical licenses satisfy the federal concept of a qualifying state-issued medical marijuana license.
- Whether state administrative rules require modification.
- Whether inspection procedures should change.
- Whether new reporting requirements may eventually become necessary.
- Whether state guidance concerning DEA registration should be issued.
- Whether future federal implementation by the Drug Enforcement Administration, Food and Drug Administration, Internal Revenue Service, or other agencies would require corresponding state action.
None of those questions could be answered solely by reading the federal order itself.
Consequently, Michigan’s decision to conduct additional review before issuing definitive implementation guidance reflected a cautious administrative approach rather than institutional indecision.
Comparing Michigan to Other States
Michigan’s measured response also illustrates how differently states have approached the same federal event.
California moved relatively quickly to publish implementation resources, explain opportunities for qualifying medicinal licensees, discuss DEA registration, and modify certain administrative procedures intended to facilitate participation within the evolving federal framework.²
Oklahoma similarly issued detailed public guidance, but reached a different conclusion regarding implementation strategy.
Rather than modifying licensing procedures, the Oklahoma Medical Marijuana Authority repeatedly emphasized that Oklahoma law remained controlling while publishing detailed answers concerning packaging, labeling, taxation, DEA registration, emergency rulemaking, and interstate commerce.³
New Mexico likewise informed licensees that the federal order did not automatically modify existing state statutes or administrative regulations and instructed businesses to continue complying with current state requirements until state law itself changed.⁴
Washington addressed yet another question.
Rather than concentrating primarily upon implementation logistics, the Washington State Liquor and Cannabis Board publicly analyzed whether much of Washington’s licensing structure even fell within the scope of the federal medical cannabis framework because of the state’s integrated regulatory model.⁵
Each of these jurisdictions reached different conclusions—or emphasized different aspects—of the same federal development.
Michigan’s distinguishing characteristic is not necessarily that it adopted a more cautious approach.
Rather, it is that the agency expressly advised stakeholders that additional guidance would follow after completion of its review.
That public commitment naturally created expectations among regulated businesses that a subsequent implementation document would eventually appear.
Why Additional Guidance Matters
Some observers may reasonably ask whether additional state guidance is necessary at all if Michigan businesses must simply continue following existing state law.
The answer lies in the practical realities of operating a regulated industry.
Cannabis licensees routinely make significant financial and operational decisions long before legal questions receive definitive judicial resolution.
Businesses evaluate whether to expand facilities.
Investors determine whether additional capital should be committed.
Accountants analyze changing federal tax treatment.
Compliance officers revise internal policies.
Attorneys advise clients concerning regulatory risk.
Lenders evaluate credit exposure.
Insurers assess underwriting decisions.
Clear public guidance from regulators reduces uncertainty across each of those areas.
Even guidance stating that “no immediate operational changes are required” provides valuable regulatory certainty when accompanied by an explanation of the agency’s legal reasoning.
Conversely, where agencies announce that a comprehensive review is underway but do not subsequently publish the anticipated analysis, businesses remain uncertain regarding whether additional changes may still be forthcoming.
That uncertainty can influence business planning even if regulators ultimately determine that no substantive changes are necessary.
The issue therefore extends beyond legal compliance.
It concerns regulatory communication.
For industries operating under complex administrative frameworks, predictable communication often carries significant practical value independent of any underlying legal changes.
What Has the CRA Published Since April?
Following its April 23 announcement, the Cannabis Regulatory Agency continued publishing a steady stream of official communications addressing numerous aspects of Michigan’s regulated cannabis industry.
Those public announcements demonstrate an agency that remains actively engaged in carrying out its statutory responsibilities.
The CRA has continued issuing product recalls, announcing formal disciplinary actions against licensees, publishing notices of proposed administrative rule changes, scheduling public hearings, updating licensing information, and informing stakeholders regarding routine regulatory developments.¹²
Those activities are significant because they demonstrate that federal rescheduling has not displaced the agency’s broader regulatory mission.
Michigan’s cannabis industry continues to require day-to-day oversight involving product safety, licensing integrity, administrative enforcement, and rulemaking regardless of changes occurring at the federal level.
At the same time, those routine regulatory functions differ fundamentally from the implementation guidance contemplated by the agency’s April 23 statement.
The April announcement suggested that the CRA intended to undertake a specific legal analysis addressing the practical implications of the federal Schedule III order and to communicate the results of that analysis publicly.
Routine enforcement announcements, while important, do not answer the implementation questions that prompted the original commitment.
Questions That Public Guidance Could Answer
If Michigan ultimately publishes the comprehensive implementation guidance referenced in April, several issues would likely be of immediate interest to licensees.
Qualifying State Licenses
One of the most important questions involves the federal order’s reference to marijuana distributed pursuant to a “qualifying state-issued medical marijuana license.”
Michigan operates a mature medical cannabis program alongside its adult-use market.
Would the CRA conclude that existing Michigan medical licenses satisfy the federal framework?
Would any additional state action become necessary?
Would licensees seeking federal participation require supplemental approvals?
These questions remain particularly significant for businesses evaluating long-term operational strategy.
DEA Registration
California has publicly discussed DEA registration opportunities.
Oklahoma has acknowledged the issue while emphasizing continued compliance with state law.
Michigan has not yet publicly issued similarly detailed implementation guidance explaining whether, when, or under what circumstances state licensees should consider pursuing DEA registration.
That does not necessarily indicate disagreement with either California or Oklahoma.
Rather, it reflects the absence of a publicly released Michigan analysis addressing the subject.
Tax Planning
Federal Schedule III status has generated considerable discussion regarding Internal Revenue Code § 280E and the potential availability of ordinary business deductions for qualifying medical cannabis businesses.
While definitive answers ultimately depend upon federal law, state implementation guidance could nevertheless assist businesses by identifying how Michigan interprets the relationship between its licensing system and the federal framework.
Compliance Programs
Businesses also benefit from understanding whether regulators anticipate changes involving inspections, recordkeeping, reporting obligations, packaging, labeling, or future administrative procedures.
Even if the CRA ultimately concludes that existing Michigan requirements remain unchanged, a formal explanation would provide businesses with additional confidence as they develop compliance strategies.
Silence Should Not Be Confused With Inaction
It is important to distinguish between the absence of public implementation guidance and the absence of governmental activity.
Administrative agencies frequently conduct substantial legal analysis outside public view.
Agency attorneys review statutes.
Policy staff evaluate regulatory implications.
Officials consult with governors’ offices, attorneys general, legislators, and federal agencies.
Internal memoranda may circulate for months before any public announcement occurs.
Consequently, the absence of publicly available implementation guidance does not establish that the CRA has failed to evaluate the federal order.
Nor does it suggest that Michigan has ignored federal developments.
Rather, it reflects the difference between internal governmental deliberation and external regulatory communication.
For regulated industries, however, that distinction matters.
Businesses cannot rely upon internal legal memoranda that have not been released.
Instead, they must make operational decisions based upon statutes, regulations, published guidance, formal agency statements, and other publicly available sources.
From that perspective, publicly issued implementation guidance serves an important function even when regulators ultimately determine that existing requirements remain unchanged.
It provides transparency.
It reduces uncertainty.
And it allows regulated businesses to understand how their own regulator interprets one of the most significant federal cannabis developments in modern history.
Regulatory Communication Is Itself a Form of Regulation
One lesson emerging from the federal medical cannabis rescheduling process is that regulatory communication has become an increasingly important component of modern cannabis governance.
Cannabis regulation has never depended solely upon statutes and administrative rules.
Licensees routinely rely upon agency bulletins, policy memoranda, advisory opinions, compliance alerts, frequently asked questions, enforcement guidance, educational webinars, and public statements to understand how regulators interpret existing law.
Those communications frequently shape business conduct even though they do not themselves carry the force of formally adopted administrative rules.
Consequently, the manner in which agencies communicate significant legal developments may substantially influence industry behavior long before legislatures amend statutes or agencies promulgate new regulations.
That principle appears particularly relevant following the Department of Justice’s April 2026 medical cannabis rescheduling order.
California has emphasized administrative implementation.
Oklahoma has published detailed operational guidance while reinforcing continued compliance with existing state law.
New Mexico has explained that federal action does not automatically amend state law.
Washington has publicly addressed structural questions regarding the applicability of the federal framework to its licensing system.
Michigan, by contrast, publicly announced that additional analysis would occur before comprehensive implementation guidance would be issued.
Each approach represents a different method of regulatory communication.
None necessarily reflects disagreement concerning federal law itself.
Instead, they reflect differing institutional judgments concerning how and when regulators should communicate evolving legal developments to the industries they supervise.
The Value of Predictability
Predictability remains one of the most valuable characteristics of any regulatory system.
Businesses generally can adapt to changing legal requirements provided they understand those requirements with sufficient clarity to plan accordingly.
Uncertainty, by comparison, often produces greater operational challenges than regulation itself.
Cannabis businesses routinely make decisions involving long-term leases, cultivation facilities, manufacturing equipment, inventory management, staffing, financing, mergers, acquisitions, insurance, and tax planning.
Those decisions frequently involve obligations extending years into the future.
Accordingly, businesses benefit not only from knowing what the law currently requires, but also from understanding how regulators anticipate implementing major legal developments.
The CRA’s April 23 announcement recognized this reality.
Rather than immediately interpreting every consequence of federal rescheduling, the agency promised additional review before reaching definitive conclusions.
That cautious approach reflected responsible administrative decision-making.
At the same time, regulated businesses naturally continue monitoring for the completion of that publicly announced review because its conclusions may affect future operational planning.
Looking Ahead
Federal medical cannabis rescheduling represents neither the beginning nor the end of cannabis regulatory reform.
Instead, it marks another stage in the continuing evolution of state-federal cannabis policy.
Additional federal implementation guidance will likely emerge.
Future DEA policies may clarify registration procedures.
Congress could consider additional statutory reforms.
Federal courts may ultimately interpret unresolved provisions of the April 2026 order.
State legislatures likewise may amend existing licensing statutes, revise controlled-substance schedules, or direct cannabis agencies to adopt new administrative rules.
Michigan itself may determine that no significant regulatory modifications are presently necessary.
Alternatively, future federal developments could prompt the CRA to issue the additional implementation guidance referenced in April.
Either outcome would represent a legitimate policy choice.
The important consideration is that businesses benefit when those choices are communicated clearly and publicly.
Conclusion
Michigan’s April 23 announcement reflected an agency appropriately recognizing both the significance of federal medical cannabis rescheduling and the complexity of its implementation.
The CRA did not promise immediate regulatory change.
It promised careful analysis.
A review of the agency’s publicly available announcements through late July 2026 indicates that Michigan has remained actively engaged in regulating its cannabis industry through recalls, disciplinary actions, rulemaking activities, and other routine regulatory functions.
At the same time, the specific comprehensive implementation guidance referenced in the April announcement does not appear among the publicly available materials reviewed for this article.
That observation should not be interpreted as criticism.
Nor should it be understood as evidence that no internal legal analysis has occurred.
Rather, it reflects a straightforward factual observation regarding the agency’s public communications.
As federal medical cannabis implementation continues to develop, Michigan’s regulated industry will likely continue looking to the CRA for additional guidance regarding how the state’s regulatory framework intersects with evolving federal law.
Whether that guidance ultimately confirms that existing practices remain appropriate or identifies future operational adjustments, its publication would provide valuable clarity for the businesses, professionals, investors, attorneys, patients, and policymakers who rely upon Michigan’s cannabis regulatory system.
Footnotes
- Michigan Cannabis Regulatory Agency, Press Release: Federal Order Rescheduling Cannabis (Apr. 23, 2026). (Michigan
)
- Id. (Michigan
)
- Michigan Cannabis Regulatory Agency, Michigan’s Cannabis Regulatory Agency Comments on the Proposed Federal Rule Rescheduling Marijuana (July 22, 2024). (Michigan
)
- Michigan Cannabis Regulatory Agency, Statement from Michigan Cannabis Regulatory Agency Executive Director Brian Hanna (Dec. 18, 2025); Michigan Cannabis Regulatory Agency, Dec. 19, 2025 Statement from CRA Executive Director Brian Hanna (Dec. 19, 2025). (Michigan
)
- Michigan Cannabis Regulatory Agency, News Releases (reviewing April–July 2026 public announcements). (Michigan
)
- Id. (Michigan
)
- Michigan Cannabis Regulatory Agency, Press Release: Federal Order Rescheduling Cannabis (Apr. 23, 2026).
- California Department of Cannabis Control, Federal Rescheduling Resources.
- Oklahoma Medical Marijuana Authority, Update: OMMA Monitors DEA Rescheduling Status; Frequently Asked Questions (May 2026).
- New Mexico Cannabis Control Division, Industry Bulletin 26-07 (June 16, 2026).
- Washington State Liquor & Cannabis Board, Federal Medical Cannabis Rescheduling Guidance (June 2026).
- Michigan Cannabis Regulatory Agency, News Releases, https://www.michigan.gov/cra/news-releases (reviewed Apr.–July 2026).
- Michigan Cannabis Regulatory Agency, Press Release: Federal Order Rescheduling Cannabis (Apr. 23, 2026).
- California Department of Cannabis Control, Federal Rescheduling Resources.
- Oklahoma Medical Marijuana Authority, Update: OMMA Monitors DEA Rescheduling Status; Frequently Asked Questions (May 2026).
- I.R.C. § 280E.
- See California Department of Cannabis Control, Federal Rescheduling Resources; Oklahoma Medical Marijuana Authority, Update: OMMA Monitors DEA Rescheduling Status; New Mexico Cannabis Control Division, Industry Bulletin 26-07; Washington State Liquor & Cannabis Board, public guidance regarding federal medical cannabis rescheduling.
- Michigan Cannabis Regulatory Agency, Press Release: Federal Order Rescheduling Cannabis (Apr. 23, 2026).
- Michigan Cannabis Regulatory Agency, News Releases, https://www.michigan.gov/cra/news-releases (reviewed through late July 2026).
- Id.
I want to sing like the birds sing, not worrying about who hears or what they think. – Rumi
WeedPress: The Paper Trail 
Leave a comment